iPSC PlatformsCell & Gene TherapiesRegenerative Medicine

Engineering the next generation of living medicines

Building next-generation cell and gene therapy platforms, gene-edited living medicines, and autonomous biomanufacturing systems that accelerate clinical translation — at scale and at speed — with iPSC technology at the core.

Explore our platformsView publications
62+Publications
32+Patents
1,200+iPSC Lines
8+GMP iPSC Lines
25+Years in science

Research Programs

Four integrated platforms, one manufacturing backbone.

All research programs
01

The foundational layer for everything we build.

iPSC Platform & Cell Differentiation

Our iPSC core operates as the backbone of every therapeutic program — from cGMP-grade reprogramming and banking to scalable directed differentiation into clinically relevant cell types. We maintain the world's largest ALS patient iPSC biorepository and have established robust protocols across cardiovascular, neurological, and metabolic lineages.

cGMP iPSC BankingEndothelial DifferentiationIslet β-cellNeural / Motor NeuronCardiomyocytesBioreactor Scale-UpDisease Modeling Lines
Explore platform
02

Engineering cells that do what drugs cannot.

Cell & Gene-Edited Therapies

We engineer hypoimmune, off-the-shelf cell therapies using CRISPR-based gene editing to create universal donor iPSC lines. Our pipeline spans vascular progenitors for critical limb ischemia, insulin-secreting beta cells for T1D, and CAR-T/NK platforms for immuno-oncology — all supported by IND-enabling CMC infrastructure at our cGMP facility.

Hypoimmune EngineeringVascular ProgenitorsIslet Cell TherapyImmunotherapyCardiac Cell TherapyCRISPR EditingIND-Enabling CMC
Explore platform
03

Building complexity from the ground up.

Bioengineered Tissues & Organoids

From vascularized cardiac constructs to bioengineered pancreas systems, we build multi-cellular tissue architectures that recapitulate native organ physiology. Our organ-on-chip and organoid platforms serve as next-generation alternatives to animal models (NAMs) for disease modeling and drug screening.

Vascularized Cardiac TissueCardiomyocyte Disease ModelsPrevascularized ConstructsVascular OrganoidsBioengineered PancreasOrgan-on-ChipBiomaterial ScaffoldsNAMs Platforms
Explore platform
04

Making cell therapy as reliable as semiconductor fabrication.

Robotics, Automation & AI

We're building closed-loop, AI-integrated biomanufacturing infrastructure where robotic systems handle iPSC reprogramming, differentiation, and QC — eliminating batch-to-batch variability. Machine learning models score colony morphology, predict process deviations, and optimize bioprocess parameters in real time.

Automated iPSC ReprogrammingAutologous ManufacturingRobotic DifferentiationModular Gene EditingML Process OptimizationReal-Time CQA MonitoringDigital TwinsAI Colony Scoring
Explore platform

Disease Focus

From discovery to clinic across six therapeutic areas.

Active programs
Critical Limb IschemiaType 1 DiabetesCardiomyopathyALSSpinal Muscular AtrophyImmuno-Oncology
Expanding areas
Cardiovascular DiseaseMetabolic DisordersNeurodegenerative Disease

Biomanufacturing Center

A 25,000 sq ft cGMP facility built for clinical-grade cell therapy.

The Cedars-Sinai Biomanufacturing Center operates as a Partnership Development Manufacturing Organization (PDMO) — an academic-industrial engine providing cGMP manufacturing services, incubating early-stage companies, and translating novel therapies toward IND.

12+Cell types in GMP
8+GMP iPSC Lines
3+Reprogramming partners
$25M+Industry contracts
Partner with us

ISO-Certified Cleanroom Suites

Class 100/10,000 cleanrooms for GMP cell manufacturing with controlled access and environmental monitoring.

Automated Differentiation Labs

Robotic platforms for scalable, reproducible iPSC reprogramming and directed differentiation at scale.

AI-Integrated Bioprocessing

Real-time CQA monitoring, ML colony scoring, and closed-loop process optimization infrastructure.

IND-Enabling CMC Support

Full regulatory support from process development to IND submission, including quality management systems.

Ready to collaborate?

Where academic depth meets industrial scale.

Co-develop, co-invest, and co-translate with the Cedars-Sinai Biomanufacturing Center.

Explore partnershipsContact us